Esophageal Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Esophageal cancer is a male-dominant aggressive malignancy and a leading cause of cancer-related mortality globally. The epithelium of the esophagus has historically been the site of malignant neoplasia and is still a major site of cancer formation. Squamous cell carcinoma and adenocarcinoma are the two predominant histological subtypes, with the varying geographical and racial distribution.
Esophageal cancer marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for esophageal cancer.
Leading Marketed Drugs for Esophageal Cancer
Some of the leading marketed drugs for esophageal cancer are pembrolizumab, Nivolumab, and others. Programmed cell death protein 1 (PD1 or CD279 or PDCD1) antagonist is the therapy class of pembrolizumab.
Esophageal Cancer Marketed Drugs Segmentation by Mechanism of Action
The key mechanisms of action for esophageal cancer marketed drugs are genes, nucleic acids, and related component inhibitors, enzyme inhibitors, protein and peptide inhibitors, receptor antagonists, and receptor inhibitors.
Esophageal Cancer Marketed Drugs Analysis, by Mechanism of Action (%)
For more MoA insights into esophageal cancer marketed drugs market, download a free report sample
Leading Pipeline Drugs for Esophageal Cancer
Some of the leading pipeline drugs for esophageal cancer are tislelizumab, Serplulimab, pembrolizumab, nivolumab, ipilimumab + nivolumab, and others. Of all the pipeline drugs for esophageal cancer, both molecules currently present in the pre-registration phase of development are targeting PD1.
Esophageal Cancer Pipeline Drugs Market Segmentation by Mechanism of Action
The key mechanisms of action for esophageal cancer pipeline drugs are cytotoxic to cells, receptor antagonist, enzyme inhibitor, protein & peptide inhibitor, receptor agonist, transporter inhibitor, and others.
Esophageal Cancer Pipeline Drugs Market Analysis, by Mechanisms of Action (%)
For more MoA insights into the esophageal cancer pipeline drugs market, download a free report sample
Esophageal Cancer Pipeline/Marketed Drugs Market Segmentation by Routes of Administration
The key routes of administration for esophageal cancer pipeline and marketed drugs are injection, oral, and topical.
Esophageal Cancer Pipeline/Marketed Drugs Market Analysis, by Routes of Administration (%)
For more routes of administration insights into the esophageal cancer pipeline/marketed drugs market, download a free report sample
Esophageal Cancer Pipeline Drugs Market Segmentation by Molecule Type
The key molecule types for the esophageal cancer pipeline drugs are biologic, small molecule, and oligonucleotide.
Esophageal Cancer Pipeline Drugs Market Analysis, by Molecule Types (%)
For more molecule type insights into the esophageal cancer pipeline drugs, download a free report sample
Esophageal Cancer Marketed and Pipeline Drugs Market – Competitive Landscape
Some of the top players in esophageal cancer marketed and pipeline drugs market are BioStar Pharmaceuticals, Chugai Pharmaceuticals, Shionogi & co, and others.
Esophageal Cancer Marketed/Pipeline Drugs Market Report Overview
Key Mechanisms of Action (Marketed Drugs) | Genes, Nucleic Acids, and Related Component Inhibitors, Enzyme Inhibitors, Protein and Peptide Inhibitors, Receptor Antagonist, and Receptor Inhibitor |
Key Mechanisms of Action (Pipeline Drugs) | Cytotoxic To Cell, Receptor Antagonist, Enzyme Inhibitor, Protein & Peptide Inhibitor, Receptor Agonist, Transporter Inhibitor, and Others |
Key Routes of Administration (Marketed/Pipeline Drugs) | Injection, Oral, and Topical |
Key Molecule Types (Pipeline Drugs) | Biologic, Small Molecule, and Oligonucleotide |
Top Players | BioStar Pharmaceuticals, Chugai Pharmaceuticals, Shionogi & co, and Others |
Esophageal Cancer Marketed Drugs Market MoA Outlook (No of Drugs)
- Genes
- Nucleic Acids and Related Component Inhibitors
- Enzyme Inhibitors, Protein and Peptide Inhibitors
- Receptor Antagonist
- Receptor Inhibitor
Esophageal Cancer Pipeline Drugs Market MoA Outlook (No of Drugs)
- Cytotoxic To Cell
- Receptor Antagonist
- Enzyme Inhibitor
- Protein & Peptide Inhibitor
- Receptor Agonist
- Transporter Inhibitor
- Others
Esophageal Cancer Marketed/ Pipeline Drugs Market RoA Outlook (No of Drugs)
- Injection
- Oral
- Topical
Esophageal Cancer Pipeline Drugs Market Molecule Types Outlook (No of Drugs)
- Biologic
- Small Molecule
- Oligonucleotide
Scope
GlobalData’s Esophageal cancer: Competitive Landscape combines data from the pharma intelligence center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Esophageal cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Esophageal cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for esophageal cancer marketed drugs market?
The key mechanisms of action for esophageal cancer marketed drugs are genes, nucleic acids, and related component inhibitors, enzyme inhibitors, protein and peptide inhibitors, receptor antagonists, and receptor inhibitors.
-
What are the key mechanisms of action for esophageal cancer pipeline drugs market?
The key mechanisms of action in the esophageal cancer pipeline drugs market are cytotoxic to cell, receptor antagonist, enzyme inhibitor, protein & peptide inhibitor, receptor agonist, transporter inhibitor, and others.
-
What are the key routes of administration for esophageal cancer marketed and pipeline drugs market?
The key routes of administration for esophageal cancer pipeline and marketed drugs are injection, oral, and topical.
-
What are the key molecule types for esophageal cancer pipeline drugs market?
The key molecule types in the esophageal cancer pipeline drugs market are biologic, small molecule, and oligonucleotide.
-
Who are the top players for esophageal cancer marketed and pipeline drugs market?
Some of the top players in the esophageal cancer marketed and pipeline drugs market are BioStar Pharmaceuticals, Chugai Pharmaceuticals, Shionogi & co, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.